National Bank of Canada
CLDX icon

National Bank of Canada’s Celldex Therapeutics CLDX Stock Holding History

National Bank of Canada’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.6K Sell
366
-1
-0.3% -$27 ﹤0.01% 2297
2025
Q4 		$9.97K Hold
367
– – ﹤0.01% 2317
2025
Q3 		$9.49K Buy
367
+1
+0.3% +$23 ﹤0.01% 2335
2025
Q2 		$7.45K Sell
366
-1
-0.3% -$19 ﹤0.01% 2412
2025
Q1 		$6.66K Sell
367
-14
-4% -$313 ﹤0.01% 2320
2024
Q4 		$9.63K Hold
381
– – ﹤0.01% 2339
2024
Q3 		$12.9K Hold
381
– – ﹤0.01% 2027
2024
Q2 		$14.9K Buy
381
+13
+4% +$491 ﹤0.01% 2041
2024
Q1 		$14.7K Hold
368
– – ﹤0.01% 2097
2023
Q4 		$14.9K Hold
368
– – ﹤0.01% 2079
2023
Q3 		$10.1K Hold
368
– – ﹤0.01% 2194
2023
Q2 		$12.5K Hold
368
– – ﹤0.01% 2123
2023
Q1 		$13.2K Buy
368
+366
+18,300% +$15.8K ﹤0.01% 2066
2022
Q4 		$89 Hold
2
– – ﹤0.01% 2717
2022
Q3 		$0 Hold
2
– – ﹤0.01% 2716
2022
Q2 		$0 Hold
2
– – ﹤0.01% 2806
2022
Q1 		$0 Buy
2
+1
+100% +$32 ﹤0.01% 2867
2021
Q4 		$0 Buy
+1
New +$44 ﹤0.01% 2807

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

National Bank of Canada's CLDX Position: Q1 2026 in Review

National Bank of Canada reduced its Celldex Therapeutics (CLDX) stake by 0.27% in Q1 2026, selling an estimated $27 and leaving 366 shares worth $11.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2297.

National Bank of Canada first reported a position in CLDX in Q4 2021 and has held it in 18 quarters since. The position peaked at $14.9K in Q2 2024. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.

  • National Bank of Canada held 366 shares of Celldex Therapeutics worth $11.6K as of Q1 2026.
  • National Bank of Canada sold 1 Celldex Therapeutics share in Q1 2026, an estimated $27.
  • Celldex Therapeutics made up ﹤0.01% of National Bank of Canada's portfolio in Q1 2026, its #2297 holding.
  • National Bank of Canada first reported a position in Celldex Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • National Bank of Canada's Celldex Therapeutics position peaked at $14.9K in Q2 2024.
  • 228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.